The Relationship between the Drug Concentration Profiles in Plasma and the Drug Doses in the Colon

Abstract

After the dosing of an extended-release (ER) formulation, compounds may exist in solutions at various concentrations in the colon because the drugs are released at various speeds from the ER dosage form. The aim of this study was to investigate the relationship between the drug concentration profiles in plasma and the drug doses in the colon. Several drug solutions of different concentrations were directly administered into the ascending colon of dogs using a lubricated endoscope, and the effects of the drug dose on colonic absorption were estimated. As a result, dose-dependency of colonic absorption varied from compound to compound. Although the relative bioavailability of colonic administration of diclofenac, metformin and cevimeline compared to oral administration was similar regardless of the drug doses in the colon, colonic absorption of diltiazem varied according to the doses. From the results of the co-administration of verapamil and fexofenadine, it was clear that diltiazem underwent extensive hepatic and gastrointestinal first-pass metabolism, resulting in a low area under the curves (AUC) at a low drug dose. During the design of oral ER delivery systems, a colonic absorption study of candidate compounds should be carried out at several solutions of different drug concentrations and assessed carefully.

Metformin loaded non-ionic surfactant vesicles: optimization of formulation, effect of process variables and characterization

“…The oral bioavailability of Metformin is 50-60% as it is BCS (Biopharmaceutical Classification System) class III drug and has site-specific absorption in the GI tract [13]. The drug has negligible plasma protein binding, relatively short half life of 1.5-4.5 hours and requires administration of 500 mg dose two or three times a day [14].…”

Transdermal delivery of antidiabetic drugs: formulation and delivery strategies

“…The drug has negligible plasma protein binding, relatively short half-life of 1.5-4.5 h and requires a dose of 500 mg two or three times daily [69][70][71]. Moreover, the drug suffers from serious but rare side-effects of lactic acidosis with 50% mortality, chest pain and allergic reactions accompanied by high incidences of concomitant gastrointestinal symptoms such as diarrhea, abdominal discomfort, vomiting, stomachache, headache and lethargy [72].…”